- Home
- » Tags
- » Lisdexamfetamine
Top View
- Lisdexamfetamine for the Management of Acute Methamphetamine Withdrawal: Protocol for an Open-Label Safety and Feasibility Study
- Efficacy of Lisdexamfetamine in Adults with Moderate to Severe Binge
- Download 2019 Aggregate Production Quota NPRM
- Dopaminergic Stimulants and Risk of Parkinson's Disease
- Vyvanse (Lisdexamfetamine)
- Treatment of Stimulant Use Disorders: Current Practices and Promising Perspectives
- Algorithm for the Psychopharmacological Management of Attention Deficit Hyperactivity Disorder (ADHD) Revised May 2009 Steven R
- Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa
- Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity Gitanjali Srivastava 1, Claudia K
- (12) United States Patent (10) Patent No.: US 8,779,191 B2 Bauer Et Al
- Efficacy of Lisdexamfetamine Dimesylate in Adults with Attention
- Prescribing Guidelines for Behavioral Health
- A Study Protocol for a Randomised, Double-Blind, Placebo Controlled Trial of Lisdexamfetamine for the Treatment of Methamphetamine Dependence
- Advanced ADHD Psychopharm
- (12) United States Patent (10) Patent No.: US 8,318,813 B2 Sanfilippo (45) Date of Patent: Nov
- Pharmaabkommen A1 E
- Repurposing Low Dose Lisdexamfetamine As Agonist Therapy for Stimulant Use Disorder: a Case Series
- Stimulant Comparisons
- ADHD Medications: Basics
- Safety and Tolerability of Oral Lisdexamfetamine In
- FDA Approved Stimulant Medications for Adult ADHD
- Perioperative Medication Guidelines – 2019
- Clinical Pharmacology and Biopharmaceutics Review(S)
- Stimulants and Related Agents
- Lisdexamfetamine Toxicity with Delayed Hypertensive Emergency
- Product Information for Lisdexamfetamine Dimesilate
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances 2009
- Tepzz 5 58¥Zb T
- Live Fast, Die Young? a Review on the Developmental Trajectories of ADHD Across the Lifespan
- 2016.05 Central Nervous System Stimulants Drug Class Review.Pdf
- 2019 Quarter 4
- Lisdexamfetamine Dimesylate) C- II Rx Only
- Systematic Literature Review on Stimulant Use and HIV (B) Part 5/5
- Narcotic Drugs and Psychotropic Substances (Consolidation) (Amendment of Schedule) Order 2017
- Drugs of Abuse, a DEA Resource Guide (2020 Edition)
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Lisdexamfetamine for Attention Deficit Hyperactivity Disorder
- Amphetamines: Potent Recreational Drug of Abuse Md
- Methylphenidate, Dexamfetamine, Lisdexamfetamine, Atomoxetine
- Methylphenidate, Atomoxetine, Dexamfetamine and Lisdexamfetamine
- Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy
- CME) Modules on Binge-Eating Disorder (BED
- Lisdexamfetamine Pre‐Review Report
- Safety Comparison of Atomextine and Lisdexamfetamine: Using
- 2019.06 CNS Stimulants for ADHD Report.Pdf
- Takotsubo Cardiomyopathy Due to Combined Use of Phentermine and Lisdexamfetamine
- Australian Public Assessment for Lisdexamfetamine Dimesilate
- Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults with Attention-Deficit/Hyperactivity Disorder
- The 2016 “Research on Drug Evidence” Report [From the 18Th ICPO / INTERPOL Forensic Science Symposium]
- Chiral Drug Analysis in Forensic Chemistry: an Overview
- Stimulants and Related Agents Pa Summary
- Australian Public Assessment Report for Lisdexamfetamine Dimesilate
- Federal Register/Vol. 81, No. 193/Wednesday, October 5, 2016
- VYVANSE ® (Lisdexamfetamine Dimesylate) Capsules, for Oral Use, CII Been Reported
- Distinct Acute Effects of LSD, MDMA, and D-Amphetamine in Healthy Subjects
- Hunter Researchers Trialling Treatment for Methamphetamine 'Ice
- Study Protocol and Rationale Phentermine-Topiramate ER Study
- AMPHETAMINES Adderall, Adderall XR (Mixed Salts of a Single Entity